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A double blind randomised trial is the gold standard
approach to minimise the introduction of bias from trial
participants, healthcare professionals and clinical trial
staff. Similarly, the use of a placebo is ideal when parti-
cipant self-reported Quality of Life is one of the primary
objectives. However, the combination of these trial
design components can present challenging ethical and
practical issues for good trial conduct.
TRYMS is a randomised, double-blinded, placebo con-
trolled phase IV clinical trial in young male cancer survi-
vors with low testosterone levels. The trial is designed to
investigate whether testosterone treatment will result in a
reduction of truncal fat mass and an increase in partici-
pant self-reported physical functioning scores and
recruited 136 participants from 10 centres across the UK.
Practical issues relate to the potential for centre and
trials unit staff to be unblinded by access to clinical data:
for example, retests of testosterone measurements
required for dose titration were required in the active
arm but were done in the placebo arm to maintain the
blind. Other issues relate to managing Investigational
Medicinal Product supply requirements: a minimisation
programme is used to ensure treatment groups are well-
balanced by randomising centre however, a random ele-
ment and participant replenishment halfway during treat-
ment can result in a temporary skew to a centre’s IMP
requirements. The ethical issues relate to non-emergency
requests for unblinding due to participant perception of
treatment allocation.
Our experiences in TRYMS, along with our solutions,
will be presented with considerations for the manage-
ment of similar trials.
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